Syngene International LimitedQ1 FY27 Results & Financial Update
Syngene International Limited: Q1 FY27 consolidated results and company financials – revenue ₹736.00 Cr, PAT ₹-9.00 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Syngene International price & chart
Market price₹359.95
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Syngene International Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Syngene International Limited reported its financial and operational performance for the first quarter of fiscal year 2027 (Q1 FY27), reflecting a challenging operating environment marked by specific client headwinds and forex movements.
Revenue from operations for the quarter stood at Rs. 736 crore, down 16% compared to Rs. 875 crore in the corresponding quarter of the previous year (Q1 FY26).
Operating performance was impacted by a lack of product offtake from a major biologics client and foreign exchange hedge losses, which were partially cushioned by ongoing internal cost optimization initiatives.
Operating EBITDA for Q1 FY27 was recorded at Rs. 91 crore, resulting in an operating EBITDA margin of 12%, compared to 24% in Q1 FY26.
During the quarter, the company experienced leadership changes with Kiran Mazumdar-Shaw taking on the role of Executive Chairperson and Siddharth Mittal assuming office as Managing Director and CEO.
Despite near-term headwinds, management indicated expectations for business momentum to improve in the second half of the fiscal year, projecting single-digit revenue degrowth in rupee terms and full-year EBITDA margins in the mid-20s.
01 · Business model
What does Syngene International do?
Syngene International Limited is an integrated research, development, and manufacturing services (CRO/CDMO) company catering to the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.
The company operates through specialized discovery, development, and manufacturing facilities spanning over 3 million square feet across India and the United States, offering end-to-end scientific services to approximately 400 global customers.
Syngene's client base encompasses biotechnology companies pursuing cutting-edge science as well as major global multinationals such as Bristol-Myers Squibb (BMS), GSK, Zoetis, and Merck KGaA.
The business model relies on leveraging a large team of over 8,300 employees—including more than 5,700 scientists—to deliver scientific excellence, robust data security, and manufacturing capacity at speed to improve clients' time-to-market and lower the cost of innovation.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹736.00 Cr |
| Profit after tax | ₹-9.00 Cr |
Financial interpretation
What the reported numbers mean
Profit after tax represented -1.2% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove margins
Operating profitability faced pressure from forex hedge losses during the quarter.
The negative impact on margins from lower offtake and forex losses was partially offset by ongoing cost optimization initiatives implemented by the company.
04 · Demand, customers & order book
Where demand is coming from
Syngene works with approximately 400 global customers across industry segments, including biotech companies and major multinationals such as BMS, GSK, Zoetis, and Merck KGaA.
05 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The company operates over 3 million square feet of specialized discovery, development, and manufacturing facilities located across India and the U.S.
06 · Strategy & new businesses
How the company is trying to change its growth mix
Management's strategic repositioning emphasizes driving growth primarily through Contract Development and Manufacturing Operations (CDMO) and AI-led advanced services.
Syngene further strengthened Syn.AI, its AI-enabled scientific platform, by developing gigascale virtual screening capabilities for larger molecular libraries and advancing de novo (new molecule) design capabilities.
Syngene signed a Memorandum of Understanding (MoU) with BRIC-Translational Health Science and Technology Institute (THSTI) to establish an operational partnership for early and late-phase clinical development, translational research, and bioanalytical sciences, including First-in-Human (FIH) and Phase I clinical programs.
07 · Reported developments
What changed operationally
Syngene was featured in TIME Magazine and Statista's 'World's Most Sustainable Companies 2026' ranking for the second consecutive year, placing among the top 750 most sustainable companies globally out of more than 5,800 evaluated companies across 43 countries.
08 · Pressure points & risks
What is not going smoothly
The company recorded expenses of Rs. 10 crore (net of tax) under exceptional items for termination benefits extended to employees in accordance with approved policy.
09 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Capital allocation & funding
Management noted that the company continues to maintain a strong balance sheet and financial discipline, providing flexibility to invest in strategic priorities.
10 · Beyond the numbers
What changed beyond the numbers
Reported update
Board Changes
Dr. Kush Parmar stepped down as Independent Director. Dr. Vijaya Chandru (academic entrepreneur and deep-tech expert from MIT) and Dr. Arun Chandavarkar (former CEO and Joint MD of Biocon Limited) were appointed as Independent Directors.
11 · Key Q&A
The quarter, answered directly
What does Syngene International do?
Syngene International Limited is an integrated research, development, and manufacturing services (CRO/CDMO) company catering to the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.
What is the clearest takeaway from Q1 FY27?
Syngene International Limited reported its financial and operational performance for the first quarter of fiscal year 2027 (Q1 FY27), reflecting a challenging operating environment marked by specific client headwinds and forex movements.
What drove revenue or demand?
Syngene works with approximately 400 global customers across industry segments, including biotech companies and major multinationals such as BMS, GSK, Zoetis, and Merck KGaA.
What mattered most for margins or profitability?
Operating profitability faced pressure from forex hedge losses during the quarter.
What changed operationally beyond the headline numbers?
The company operates over 3 million square feet of specialized discovery, development, and manufacturing facilities located across India and the U.S.
What are the main pressure points disclosed for the quarter?
The company recorded expenses of Rs. 10 crore (net of tax) under exceptional items for termination benefits extended to employees in accordance with approved policy.
12 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.